Josias Fantato De Pontes
Director of Finance/CFO bei SIGILON THERAPEUTICS, INC.
Vermögen: - $ am 31.07.2023
Profil
Josias Fantato De Pontes is currently the Treasurer, Chief Financial & Accounting Officer at Sigilon Therapeutics, Inc. He previously worked as the Senior Director-Accounting Reporting at Catalent JNP, Inc. from 2016 to 2018, the Senior Director-Rare Diseases Finance at Genzyme Corp.
from 2011 to 2015, and the Senior Director-Financial Planning & Analysis at Zafgen, Inc. from 2017 to 2019.
Mr. De Pontes holds an MBA from The Ohio University and an undergraduate degree from Fundação Escola de Comércio Álvares Penteado.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.08.2023 | 0 ( -.--% ) | - $ | 31.07.2023 |
Aktive Positionen von Josias Fantato De Pontes
| Unternehmen | Position | Beginn |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Director of Finance/CFO | 18.02.2022 |
Ehemalige bekannte Positionen von Josias Fantato De Pontes
| Unternehmen | Position | Ende |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Corporate Officer/Principal | 31.08.2019 |
| JUNIPER PHARMACEUTICALS INC | Corporate Officer/Principal | 01.01.2018 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | 01.05.2007 |
Ausbildung von Josias Fantato De Pontes
| The Ohio University | Masters Business Admin |
| Fundação Escola de Comércio Álvares Penteado | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Catalent JNP, Inc.
 Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
